Navamedic

What Navamedic does

Navamedic ASA is a Nordic specialty pharmaceutical company founded in 2002 and listed on the Oslo Stock Exchange (ticker: NAVA), with a 45-person team operating from Oslo and Mölndal, Sweden. The company distributes a portfolio of approximately 50 brands across three business units — Consumer Health (OTC products such as Virono, a single-dose aciclovir cold sore tablet using patented Lauriad mucoadhesive buccal technology), Prescription Medicines (notably Flexilev in OraFID, a single-use Parkinson's dosing device, plus Sensidose Parkinson's products and addiction treatments added via the dne pharma acquisition), and Medical Nutrition (specialized formulas for rare metabolic disorders including PKU, GA1, IVA, UCD, MSUD, TYR, Homocystinuria, MMA/PA, plus ketogenic diet, renal, and Glycogen Storage Disease products such as Glycosade, K.Vita, and Renastart). The portfolio is anchored by two patented delivery technologies — the Lauriad mucoadhesive buccal system and the OraFID dosing device — and serves patients across multiple rare and chronic conditions with high unmet needs and limited competition.

Navamedic generates revenue through one-time product sales via pharmacy distribution (its primary channel across the Nordics, Baltics, and Benelux) and subscription-style recurring demand for chronic-condition medical nutrition. The company pursues a hybrid go-to-market: direct-to-pharmacy sales in Scandinavia and Benelux, supplemented by exclusive distribution partnerships — notably Orion Corporation for Flexilev across 27 European countries and Evolsin Medical for the German market. Reported FY2025 revenue was NOK 565.4 million with EBITDA of NOK 47.6 million, and Q3 2025 revenue grew 12.9% year-over-year to NOK 138.9 million.

The company's stated mid-term revenue target is NOK 1 billion, and growth is being driven by a combination of acquisition-led portfolio expansion (Impolin in 2022, Sensidose in 2023, dne pharma in 2025), new product launches (Virono, Flexilev in OraFID, Dermix Absolut Torr), and geographic expansion into Germany and broader Europe. Recent capital actions include a partially underwritten rights issue of approximately NOK 130 million in October 2025 to fund the dne pharma acquisition. Patient-facing adherence programs (Lighter Together, In Good Company, MyControl) and a new Parkinson's companion app developed with Alex Therapeutics round out the commercial model.

Name

Navamedic

Legal name

Navamedic ASA

Website

https://navamedic.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Navamedic ASA is a Nordic specialty pharmaceutical company that distributes approximately 50 brands across Consumer Health, Prescription Medicines, and Medical Nutrition — including Parkinson's dosing devices, rare-disease nutrition, and OTC treatments — via pharmacy channels in 16 European countries.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmacies and Drug Retailers (456110)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Nephrology & Urology Pharmaceuticals (HLAIAAAM), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Pharmaceutical products
• Prescription medicines
• Medical nutrition
• Consumer health products
• Rare disease nutrition

Headquarters

HQ city

Mölndal

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Consumer Health Products: Over-the-counter products including Virono for cold sores, sold through pharmacies. Revenue generated from product sales to consumers via pharmacy distribution.
2. Prescription Medicines: Prescription-based pharmaceutical products including Parkinson's treatments (Flexilev, Sensidose products), antibiotics, and addiction treatment medications sold to healthcare providers and patients.
3. Medical Nutrition: Specialized nutrition products for metabolic disorders, sold to patients with conditions requiring dietary management. Includes protein substitutes, low protein foods, and disease-specific nutritional formulas.
4. Acquisition-driven Growth: Revenue growth driven by acquisitions including Sensidose (Parkinson's), Impolin (obesity), and dne pharma (addiction treatment). The company reports 12.9% revenue increase in Q3 2025 driven by growth in all business areas including recent dne pharma acquisition.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Navamedic is a Nordic pharmaceutical company that develops, in-licenses, markets, and distributes a portfolio of approximately 50 brands across three categories: Consumer Health OTC products (e.g., Virono cold sore treatment), Prescription Medicines (e.g., Flexilev in OraFID for Parkinson's, Sensidose drug-device products, addiction treatment pharmaceuticals), and Medical Nutrition (specialized formulas for rare metabolic disorders, ketogenic diets, renal disease, and fat metabolism disorders). Products are sold through pharmacy networks and channel partners across 16 countries in the Nordics, Baltics, Benelux, and broader Europe.

Product overview

Navamedic is a Nordic pharmaceutical company offering a diversified portfolio of healthcare products across multiple categories: Consumer Health (OTC products like Virono® for cold sores, Modifast and MedMade for weight management, and thickening agents like Attylet Plus®), Prescription Medicines (Parkinson's treatments including Flexilev® in OraFID® and Sensidose® delivery devices, plus addiction treatment pharmaceuticals from dne pharma), and Medical Nutrition products for specialized dietary needs including metabolic disorders (protein substitutes for PKU, GA1, IVA, UCD), ketogenic diet products (K.Vita, K.Yo, K.quik®, K.Flo™), renal nutrition (Renastep™, Renastart™), fat metabolism disorders (Lipistart®, MCTProcal®), glycogen storage disease (Glycosade®), and general nutritional support. The company operates across Nordic countries, the Baltics, and Benelux, with 50 brands sold in 16 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Virono: First single-dose over-the-counter cold sore tablet using patented Lauriad mucoadhesive buccal technology
• Flexilev in OraFID
• Glycosade
• Dermix

Products and services

• Virono First over-the-counter single-dose treatment for recurrent cold sores in adults, using patented Lauriad mucoadhesive buccal technology delivering aciclovir locally from a single tablet. Available in Swedish pharmacies with expansion planned to Finland and Netherlands. Represents the first Rx-to-OTC switch of an antiviral cold sore treatment in tablet form.
• Flexilev in OraFID Single-use dosing device for personalized Parkinson's disease treatment, providing simplified and precise dosing. Available at pharmacies in Scandinavia and Europe, with Orion Corporation holding exclusive rights across 27 European countries.
• Sensidose pharmaceutical products Drug-device combination therapies for Parkinson's disease acquired through the Sensidose AB acquisition in 2023. Approved in multiple countries and focused on innovative drug delivery for movement disorders.
• dne pharma addiction treatment portfolio Addiction treatment pharmaceuticals acquired via the June 2025 acquisition of dne pharma for up to NOK 225 million, marking Navamedic's entry into the addiction treatment market in the Nordic region and Europe.
• Glycosade

Quantifiable outcome

• 12.9% revenue increase in Q3 2025
• +1 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered supporting and core.

• Alex TherapeuticssupportingTechnology or Integration · 1 March 2026Navamedic and Alex Therapeutics partnered to develop a companion app for Parkinson's treatment, enhancing the patient experience and treatment adherence for Flexilev users.
• Orion CorporationcoreChannel Partner/ Reseller/ Distributor · 9 December 2025Orion Corporation has been granted exclusive rights to market and sell Flexilev in OraFID across 27 European countries. This partnership extends Navamedic's reach significantly beyond its direct distribution capabilities in Scandinavia and Benelux.
• Evolsin MedicalcoreChannel Partner/ Reseller/ Distributor · 17 October 2025Navamedic signed an exclusive distribution agreement with Evolsin Medical for the German market. The first product to be launched in Germany is Dermix Absolut Torr, with launch expected in early 2026. Germany represents the company's largest target market so far.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Orion Corporation: Finnish specialty pharmaceutical company with broad European distribution. Directly comparable as a Nordic peer with proprietary pharma products; also a commercial partner for Navamedic's Flexilev across 27 European countries.
• Swedish Orphan Biovitrum (Sobi): Swedish-listed specialty biopharma focused on rare diseases and specialty care across Europe. Comparable given Nordic specialty-pharma positioning, rare-disease portfolio, and European commercial footprint.
• Camurus: Swedish specialty pharma with proprietary drug-delivery technology (FluidCrystal) for CNS and rare-disease applications. Comparable to Navamedic's proprietary delivery approach (OraFID, Lauriad) and Nordic specialty positioning.
• Karo Pharma: Swedish specialty pharma focused on consumer health and prescription products in the Nordics and Europe. Comparable in business model (diversified specialty pharma with consumer health + Rx) and Nordic footprint.
• BioGaia: Swedish-listed probiotic and pediatric nutrition company with established distribution across Europe and emerging markets. Comparable in Nordic specialty-nutrition consumer health positioning.
• Midsona: Swedish health and wellness company with branded organic/nutrition products across the Nordics. Comparable to Navamedic's consumer health and medical nutrition portfolio in the Nordic retail-pharmacy channel.
• Medivir: Swedish specialty pharma focused on oncology and infectious disease with proprietary candidates. Comparable Nordic specialty-pharma profile and small-cap public-company structure.

Broad incumbents

• Recipharm: Swedish CDMO and specialty pharma services provider with broad European operations. Comparable Nordic pharma industry presence but operates at a different (services/manufacturing) point of the value chain.
• Perrigo Company: Global consumer self-care leader with significant European OTC footprint, including cold-sore treatments. Comparable for Navamedic's consumer-health and OTC ambitions, though at vastly larger scale.
• Nestlé Health Science: Global leader in medical nutrition and consumer health. Comparable to Navamedic's medical nutrition portfolio across metabolic disorders and ketogenic diets, though at global scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Navamedic